A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

Phase II, open-label study assessing the efficacy and safety of the ErbB family blocker afatinib combined with letrozole in estrogen receptor-positive metastatic breast cancer (MBC) patients who had progressed on letrozole monotherapy. Adult females (N = 28) received oral afatinib (50 [n = 7], 40 [n...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Springerplus
Autors principals: Gunzer, Katharina, Joly, Florence, Ferrero, Jean-Marc, Gligorov, Joseph, de Mont-Serrat, Helene, Uttenreuther-Fischer, Martina, Pelling, Katy, Wind, Sven, Bousquet, Guilhem, Misset, Jean-Louis
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4718910/
https://ncbi.nlm.nih.gov/pubmed/26835225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-015-1601-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars